investorscraft@gmail.com

Caribou Biosciences, Inc. (CRBU)

Previous Close
$1.37
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)90.966539
Intrinsic value (DCF)0.67-51
Graham-Dodd Methodn/a
Graham Formula98.707104

Company Information

2929 7th Street
Berkeley, CA 94710
United States
Phone: 510 982 6030
Industry: Biotechnology
Sector: Healthcare
CEO: Dr. Rachel E. Haurwitz Ph.D.
Full Time Employees: 147

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.

HomeMenuAccount